Hyderabad: Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration to manufacture and market Lamivudine and Zidovudine tablets.
The tablets are the generic equivalent of ViiV Healthcare Company’s Combivir tablets and are indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children.
The product, which was approved out of Unit VII formulations facility of the company here, was ready for launch, Aurobindo Pharma said in a release on Thursday.
No comments:
Post a Comment